CIK 0001505497 · Non-accelerated filer<br>Smaller reporting company
BioRestorative Therapies, Inc.
Sign in to watch- Ticker
- BRTX
- Exchange
- Nasdaq
- Industry
- Services-Misc Health & Allied Services, NEC
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 301341024
- Phone
- (631) 760-8100
- Business address
- 40 MARCUS DRIVE, SUITE ONE, MELVILLE, NY
- Former names
- Stem Cell Assurance, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 64 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-06 | Silva Francisco VP of Research and Development | Grant or award | +11,719 | $1.60 | $19K | 171,384 |
| 2025-10-06 | Silva Francisco VP of Research and Development | Grant or award · Warrant | +11,719 | 11,719 | ||
| 2025-10-06 | ALSTODT LANCE President, CEO, COB | Grant or award | +15,625 | $1.60 | $25K | 187,497 |
| 2025-10-06 | ALSTODT LANCE President, CEO, COB | Grant or award · Warrant | +11,719 | 11,719 | ||
| 2025-02-14 | Rosa David A Director | Grant or award · Stock Option | +52,632 | 52,632 | ||
| 2025-02-14 | Williams Patrick F. Director | Grant or award · Stock Option | +52,632 | 52,632 | ||
| 2025-02-14 | Kukekov Nickolay V. Director | Grant or award · Stock Option | +52,632 | 52,632 | ||
| 2025-02-14 | Kristal Robert Eugene Chief Financial Officer | Grant or award · Stock Option | +166,492 | 166,492 | ||
| 2025-02-14 | Silva Francisco VP of Research and Development | Grant or award · Stock Option | +768,979 | 768,979 | ||
| 2025-02-14 | ALSTODT LANCE President, CEO, COB | Grant or award · Stock Option | +791,885 | 791,885 | ||
| 2024-10-28 | Broadrick Dale 10% owner | Sale | −1,112 | $1.58 | $2K | 445,933 |
| 2024-04-09 | Silva Francisco VP of Research and Development | Purchase | +6,600 | $1.25 | $8K | 155,759 |
| 2024-04-08 | Silva Francisco VP of Research and Development | Purchase | +476 | $1.13 | $538 | 147,927 |
| 2024-04-08 | Silva Francisco VP of Research and Development | Purchase | +1,232 | $1.17 | $1K | 149,159 |
| 2024-03-18 | Silva Francisco VP of Research and Development | Shares withheld for taxes | −17,193 | $1.39 | $24K | 147,451 |
| 2024-03-18 | ALSTODT LANCE President, CEO, COB | Shares withheld for taxes | −17,633 | $1.39 | $25K | 171,872 |
| 2024-02-13 | Rosa David A Director | Grant or award · Stock Option | +79,646 | 79,646 | ||
| 2024-02-13 | Williams Patrick F. Director | Grant or award · Stock Option | +79,646 | 79,646 | ||
| 2024-02-13 | Kukekov Nickolay V. Director | Grant or award · Stock Option | +79,646 | 79,646 | ||
| 2024-02-13 | Paccasassi Robert VP, QA and Reg Compliance | Grant or award · Stock Option | +219,298 | 219,298 |
Page 1 of 30 · 598 trades